Aquestive is seeking FDA approval for a product while also filing registration statements with the SEC for a stock offering.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aquestive is seeking FDA approval for a product while also filing registration statements with the SEC for a stock offering.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Aquestive (United States)
company in Warren Township, United States
Nothing else this week.
- FDA
-
SEC
Slovak company
Related events
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Elutia is trading on the Nasdaq stock exchange and requires regulatory clearance from the FDA for product launches.
- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
- FDA approval enables commercial opportunity involving CBRE Group.
Coverage
Newest first; wire copies grouped- GlobeNewswireAquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”